Jubilant Pharmova Ltd.

JUBLPHARMA

₹1069.8

-2.52% (-27.6)

Market Cap

₹17,471 Cr.

P/E

29.46

About

Jubilant Pharmova Limited, formerly known as Jubilant Life Sciences Limited, operates globally in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Novel Drugs busines… Read more

Jubilant Pharmova Limited, formerly known as Jubilant Life Sciences Limited, operates globally… Read more

Low

531

52W Range

High

1310

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Asset turnover is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Debt

Company might have issues servicing its debt
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Market Share

62 %

(as of Mar 18)

Historic

Acetic Anhydride - Domestic Market Share

0.06 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.06 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

0.01 %

(as of Feb 21)

Historic

Neurological - Market Share

0.02 %

(as of Jul 22)

Historic

Pharmaceutical Sector - Market Share

0.03 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

18 %

(as of Mar 18)

Historic

Vitamin B3 - Global Market Share

64 %

(as of Mar 18)

Historic

Vitamin B4 - Domestic Market Share

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up - Contract Research

Location Wise Break-Up - Pharmaceuticals

Location Wise Break-Up

Operating Profit Break-Up

Capex

Asset Break-Up

Operational Metrics

Australia DMF fillings (.)
Source
US DMF Filings (.)
Source
Canada DMF fillings (.)
Source
Japan DMF Filings (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Number of ANDA's Filed in Europe
Source
Number of ANDA's Approved in Europe
Source
Number of ANDA's Filed in Canada
Source
Number of ANDA's Approved by Canada
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Suppliers

Aegis Logistics Ltd.
Time Technoplast Ltd.
Balaji Amines Ltd.
GMM Pfaudler Ltd.
Deep Energy Resources Ltd. - (Amalgamated)
Ganesh Benzoplast Ltd.
TPL Plastech Ltd.

Showing 5 of 7

FAQs on Jubilant Pharmova Ltd. Business

What does Jubilant Pharmova do?

Jubilant Pharmova Limited operates globally in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Novel Drugs with a strong manufacturing presence in Radiopharmaceutical products for regulated markets.

Who are the competitors of Jubilant Pharmova?

Jubilant Pharmova major competitors are Caplin Point Lab, Eris Lifesciences, Astrazeneca Pharma I, Alembic Pharma, Sanofi India, Marksans Pharma, Pfizer.
Market Cap of Jubilant Pharmova is ₹17,471 Crs.
While the median market cap of its peers are ₹18,231 Crs.

Is Jubilant Pharmova financially stable compared to its competitors?

Jubilant Pharmova seems to be less financially stable compared to its competitors.
Altman Z score of Jubilant Pharmova is 3.36 and is ranked 8 out of its 8 competitors.

View FAQ's On Shareprice

Monopoly Companies

Companies which are dominant in a product, usually having a strong moat.

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Superstar Favourites

Companies where superstar investors like Rakesh Jhunjhunwala, Asish Kacholia have invested

Run Query

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Jun Dec Sep Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Jun Dec Sep Mar	Mar Jun Sep Dec		Mar Jun Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec